A Double-Blind, Placebo-Controlled Study of Aripiprazole Adjunctive to Antidepressant Therapy among Depressed Outpatients with Inadequate Response to Prior Antidepressant Therapy (ADAPT-A Study)Fava M. · Mischoulon D. · Iosifescu D. · Witte J. · Pencina M. · Flynn M. · Harper L. · Levy M. · Rickels K. · Pollack M.
aClinical Trials and Network Institute (CTNI), Massachusetts General Hospital, and bDepartment of Biostatistics, Boston University, Boston, Mass., cCNS Healthcare, Orlando, Fla., dMood and Anxiety Disorders Program, Mount Sinai Medical School, New York, N.Y., eBehavioral Medical Research, Staten Island, New York, N.Y., fDepartment of Psychiatry, University of Pennsylvania School of Medicine, Philadelphia, Pa., and gDepartment of Psychiatry, Rush Medical College, Chicago, Ill., USA
Background: We assessed the efficacy of low-dose aripiprazole added to antidepressant therapy (ADT) in major depressive disorder (MDD) patients with inadequate response to prior ADT. Methods: As per the sequential parallel comparison design, 225 MDD subjects were randomized to adjunctive treatment with aripiprazole 2 mg/day or placebo across two 30-day phases, with a 2:3:3 randomization ratio to drug/drug (aripiprazole 2 mg/day in phase 1; 5 mg/day in phase 2), placebo/placebo (placebo in both phases), and placebo/drug (placebo in phase 1; aripiprazole 2 mg/day in phase 2). Eligible subjects were patients whose MDD was independently deemed ‘valid’ with SAFER criteria. Subjects had been receiving ADT for ≥8 weeks, and had inadequate response to ≥1 and <4 adequate ADTs in the current episode, as defined by the Antidepressant Treatment Response Questionnaire. Results: The pooled, weighted response difference between aripiprazole 2 mg/day and placebo in the two phases was 5.6% (p = 0.18; NS). The aripiprazole 2 mg/day-placebo difference on the Montgomery-Asberg Depression Rating Scale pooled across the two phases was –1.51 (p = 0.065; NS). Other secondary endpoint analyses showed nonsignificant pooled differences favoring aripiprazole over placebo. Of the 225 randomized subjects in phase 1, 2 dropped out in both arms, while in phase 2, of 138 phase 1 placebo nonresponders, 9 dropped out on aripiprazole and 5 on placebo. There were only minimal differences in adverse event rates between treatments, except for constipation, weight gain, and dry mouth, more common on aripiprazole. Conclusions: This study provides clear support for the tolerability of low-dose aripiprazole as an ADT-augmenting agent, with marginal efficacy.
Maurizio Fava, MD
Department of Psychiatry, Massachusetts General Hospital
55 Fruit Street – Bulfinch 351
Boston, MA 02114 (USA)
Tel. +1 617 724 0838, E-Mail MFava@partners.org
In the meantime, M. Levy sadly died.
Received: December 7, 2010
Accepted after revision: August 23, 2011
Published online: January 25, 2012
Number of Print Pages : 11
Number of Figures : 1, Number of Tables : 5, Number of References : 25
Additional supplementary material is available online - Number of Parts : 1
Psychotherapy and Psychosomatics
Vol. 81, No. 2, Year 2012 (Cover Date: February 2012)
Journal Editor: Fava G.A. (Bologna)
ISSN: 0033-3190 (Print), eISSN: 1423-0348 (Online)
For additional information: http://www.karger.com/PPS